Tradestie Institutional Equity Comparison Engine

KURE vs CXSE โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-16 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

KURE Overall Edge

KURE Captures Institutional Edge (2โ€“0 Pillars ยท 2โ€“1 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to KraneShares MSCI All China Health Care Index ETF (KURE) driven by superior Momentum & Technical, Options & Structure. Fundamentally, KURE trades at N/M Forward P/E with N/A operating margin (N/A YoY revenue) versus CXSE at N/M Forward P/E and N/A operating margin (N/A YoY). In options structure, KURE sits in UNCLASSIFIED (<1st %ile IV; Dealer Gamma Walls on Pro) against CXSE sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro).

Valuation Winner Tie
KURE N/M vs CXSE N/M Fwd P/E
Growth & Margin Winner Tie
Op Margin N/A vs N/A ยท YoY N/A vs N/A
Momentum & Technical Winner KURE
1Y -9.4% vs -26.8% ยท 52W Pos 62% vs 0%
Options & Structure Winner KURE
UNCLASSIFIED (<1st %ile IV) vs UNCLASSIFIED (N/A IV)
KURE NYSE Arca
KraneShares MSCI All China Health Care Index ETF
Institutional Equity
$17.81
-1.66% 1D
Market Cap N/A
1M Return +0.91%
1Y Return -9.36%
Forward P/E N/M
Unified AI Score
50.9 / 100 HOLD
Tech 44.0 Fund 48.0 Flow 50.0 Mom 50.0
CXSE NASDAQ
WisdomTree Trust WisdomTree China ex-State-Owned Enterprises Fund
Institutional Equity
$30.80
-2.47% 1D
Market Cap N/A
1M Return -7.44%
1Y Return -26.83%
Forward P/E N/M
Unified AI Score
43.6 / 100 HOLD
Tech 39.0 Fund 54.0 Flow 50.0 Mom 60.0

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: KURE -9.36% CXSE -26.83% Spread: +17.47 pp (KURE Lead)

Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant Revenue ($B) & Operating Margin (%)
KURE TTM Op. Margin: N/A CXSE TTM Op. Margin: N/A
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on KURE vs CXSE. Trailing 12-month operating profitability (KURE N/A vs CXSE N/A) and valuation multiples (KURE N/M vs CXSE N/M Forward P/E) are benchmarked directly in Pillar 4 below.

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: KURE (2) vs CXSE (1)
Institutional Metric KURE CXSE Criterion Row Winner
Market Capitalization Scale N/A N/A Larger Scale Tie
Trailing P/E Ratio Valuation N/M N/M Lower Multiple Tie
Forward P/E Ratio Valuation N/M N/M Lower Multiple Tie
Revenue Growth (YoY) Growth N/A N/A Higher Growth Tie
Operating Margin (TTM) Profitability N/A N/A Higher Margin Tie
Net Profit Margin Profitability N/A N/A Higher Margin Tie
Return on Equity (ROE) Capital Efficiency N/A N/A Higher ROE Tie
52-Week Range Position Momentum 62% ($14โ€“$20) 0% ($31โ€“$43) Stronger Trend KURE
Beta / 30D Volatility Risk Regime 0.73ฮฒ ยท 32% Vol 0.87ฮฒ ยท 27% Vol Lower Realized Risk CXSE
Unified Institutional Score Composite Signal 50.9 / 100 (HOLD) 43.6 / 100 (HOLD) Higher Composite KURE

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full KURE vs CXSE Buy Guide
KURE UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile <1st %ile
IV Regime Compressed (<25th %ile)
Live KURE Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
CXSE UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile N/A
IV Regime Unclassified
Live CXSE Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither KURE nor CXSE registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.